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BACKGROUND: To determine the prognostic factors and treatment outcomes of patients with early-stage adenocarcinoma (AdCa)
of uterine cervix who underwent radical hysterectomy (RH).
METHODS: Patients with early-stage squamous cell carcinoma (SCCa) of the uterine cervix who underwent RH were compared with
patients with AdCa by multivariate analysis.
RESULTS: A total of 1218 patients were eligible, of which 996 (81.8%) had SCCa and 222 (18.2%) had AdCa. In multivariate analysis,
parametrial involvement and lymph node metastasis were significant factors for both recurrence-free survival(RFS) and overall survival
(OS) of patients with AdCa, whereas age, tumour size, parametrial involvement and lymph node metastasis were significant factors
for both RFS and OS of patients with SCCa. After adjusting for significant prognostic factors, patients with AdCa had significantly
poorer RFS (odds ratio (OR)¼2.07, 95% confidence interval (CI)¼1.37–3.12, P¼0.001) and OS (OR¼2.56, 95% CI¼1.65–3.96,
Po0.001) than patients with SCCa. Recurrence outside the pelvis was more frequent in AdCa than in those with SCCa (75 vs 57.8%,
P¼0.084).
CONCLUSION(S): Although RH is still acceptable for treatment of patients with AdCa, a more effective systemic adjuvant therapy
is required.
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Cervical cancer is the second most common female cancer and the
third most common cause of cancer deaths in women worldwide
(Parkin et al, 2001; Waggoner, 2003). Approximately 75% of
cervical cancers are squamous cell carcinomas (SCCas) and 15%
are adenocarcinomas (AdCas), and the remainder consists of other
rare histologic types (Kosary, 1994; Farley et al, 2003). Recently,
however, the relative proportion and the absolute incidence of
AdCa, compared with SCCa, have increased (Smith et al, 2000; Liu
et al, 2001; Sasieni and Adams, 2001). Nevertheless, there is no
uniformly accepted form of management for AdCa. As with SCCa,
patients with International Federation of Obstetrics and Gyneco-
logy (FIGO) stage IA2–IIA cervical AdCa are treated by radical
hysterectomy (RH). The prognosis of patients with AdCa after RH
is unclear, primarily because studies have been performed on small
numbers of patients. Some of these studies found that patients with
AdCa have poorer prognosis than do those with SCCa (Hopkins
and Morley, 1991; Eifel et al, 1995; Look et al, 1996; Samlal et al,
1997; Lai et al, 1999; Kim et al, 2000; Nakanishi et al, 2000),
whereas other reports found no differences in prognosis (Anton-
Culver et al, 1992; Miller et al, 1993; Shingleton et al, 1995; Grisaru
et al, 2001; Ayhan et al, 2004; Lee et al, 2006; Fregnani et al, 2008;
Kasamatsu et al, 2009). Therefore, the prognosis after RH and the
optimal management of AdCa are still a subject of debate.
The aim of this study was to clarify the treatment outcomes and
prognostic factors after RH in patients with FIGO stage IA2–IIA
AdCa of uterine cervix, and to compare them with those of patients
with SCCa to postulate the optimal management of patients with
early-stage AdCa of uterine cervix.
MATERIALS AND METHODS
From 1989 to 2006, 2350 patients with invasive cervical cancer
were treated and followed-up at the Asan Medical Center (AMC,
Seoul, Korea). After approval by the Institutional Review Board of
AMC, we searched the cancer registry and computerised database
of AMC for patients with (1) FIGO stage IA2–IIA cervical cancer,
(2) who underwent RH with pelvic and/or para-aortic lymphade-
nectomy and (3) who had the histologic types of SCCa and AdCa.
Patients who received chemotherapy, radiation therapy (RT) or
concurrent chemoradiation therapy (CCRT) before RH, and
patients with occult cervical cancer detected after simple
hysterectomy, were excluded. As the preferred treatment in our
centre for patients with FIGO stage IA2–IIA cervical cancer is RH,
almost all patients with FIGO stage IA2–IIA cervical cancer
underwent RH and only a small number of patients who were not
eligible for radical surgery because of severe medical co-morbidity
received RT or CCRT. Radical hysterectomy was completed in
patients with positive pelvic or para-aortic lymph nodes or
parametrial involvement confirmed by frozen section, although it
is still unclear whether the surgeon should complete the RH or Received 5 January 2010; revised 21 April 2010; accepted 26 April 2010
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sstop the procedure and administer CCRT if a frozen biopsy reveals
parametrial involvement or lymph node metastasis. Patients with
42 intermediate risk factors (lymphovascular space invasion
(LVSI), tumour 44cm or deep cervical stromal invasion 42 out
of 3) were recommended for adjuvant RT, whereas patients with
one or more high-risk factors (resection margin involvement,
parametrial involvement or lymph node involvement) were
recommended for adjuvant CCRT. This policy for adjuvant
therapy has been consistent during study periods. Medical records
were retrospectively reviewed, and the following parameters
were collected: age, FIGO stage, histology, grade of differentiation,
tumour size, depth of cervical stromal invasion, parametrial
involvement, resection margin status, lymphovascular space
invasion, lymph node metastasis, adjuvant therapy, date of
recurrence, location of recurrent disease, treatment at recurrence,
and date of death or last follow-up. Pathologic slides were reviewed
by two experienced pathologists at our institution. Squamous
cell carcinomas were graded histologically as well-differentiated
(grade 1; mature squamous cells with abundant keratin, pearl
formation and sometimes intercellular bridges), moderately differ-
entiated (grade 2; less abundant cytoplasm, cell borders less distinct,
nuclei with greater pleomorphism and high mitotic activity) and
poorly differentiated (grade 3; masses and nests of small, primitive-
appearing oval cells with scant cytoplasm and hyperchromatic and
spindle-shaped nuclei with high mitotic activity).
All patients were followed-up at least every 3 months for the first
2 years, at least every 6 months for the next 3 years and then every
year until recurrence or death. Recurrence-free survival (RFS) was
defined as the time, in months, from the date of RH to the date of
relapse or censoring, and overall survival (OS) was defined as the
time, in months, from the date of RH to the date of death, last
follow-up or censoring.
Statistical analysis
Frequency distributions were compared using the w
2 and Fisher’s
exact tests, and mean values were compared between groups using
Student’s t-test. The RFS and OS were estimated using the Kaplan–
Meier method and groups were compared by the log-rank test for
categorical factors and Cox’s proportional hazards model for
continuous factors, by univariate analysis. All prognostic variables
found to be significant in univariate analysis were included in
multivariate analysis using Cox’s proportional hazards model.
Stepwise backward elimination methods were used to select factors
Table 1 Characteristics of the study patients (n¼1218)
AdCa SCCa
Characteristics Total (n¼222) (n¼996) P-value
Age, years
Mean (range) 48.2 (24–86) 46.4 (25–73) 48.7 (24–86) 0.006
o30 21 (1.7%) 5 (2.3%) 16 (1.6%) 0.177
30–49 715 (58.7%) 141 (63.5%) 574 (57.6%)
450 482 (39.6%) 76 (34.2%) 406 (40.8%)
FIGO stage
IA2 88 (7.2%) 8 (3.6%) 80 (8.0%) 0.061
IB1–IB2 1019 (83.7%) 195 (87.8%) 824 (82.7%)
IIA 111 (9.1%) 19 (8.6%) 92 (9.3%)
Histologic subtype
Mucinous 203 (16.7%) 203 (16.7%) — —
Endometrioid 14 (1.1%) 14 (1.1%) —
Serou 2 (0.2%) 2 (0.2%) —
Mixed 3 (0.2%) 3 (0.2%) —
Grade of differentiation
Well 332 (27.3%) 63 (28.4%) 269 (27.0%) 0.366
Moderately 573 (47.0%) 94 (42.3%) 479 (48.1%)
Poorly 294 (24.1%) 60 (27.0%) 234 (23.5%)
Undetermined 19 (1.6%) 5 (2.3%) 14 (1.4%)
Tumour size, cm
Mean (range) 2.4 (0.3–9) 2.3 (0.3–6) 2.4 (0.4–9) 0.286
p2 571 (46.9%) 108 (48.6%) 463 (46.5%) 0.147
2–4 510 (41.9%) 94 (42.3%) 416 (41.8%)
4–6 114 (9.4%) 20 (9.0%) 94 (9.4%)
46 23 (1.9%) 0. (0.0%) 23 (2.3%)
Depth of stromal invasion
p1/2 753 (61.8%) 135 (60.8%) 618 (62.0%) 0.731
41/2 465 (38.2%) 87 (39.2%) 378 (38.0%)
Parametrial involvement
No 1106 (90.8%) 200 (90.1%) 906 (91.0%) 0.684
Yes 112 (9.2%) 22 (9.9%) 90 (9.0%)
Resection margin
Negative 1190 (97.7%) 218 (98.2%) 972 (97.6%) 0.585
Positive 28 (2.2%) 4 (1.8%) 24 (2.4%)
LVSI
No 969 (79.6%) 189 (85.1%) 780 (78.3%) 0.023
Yes 249 (20.4%) 33 (14.9%) 216 (21.7%)
Lymph node metastasis
No 1048 (86.0%) 188 (84.7%) 860 (86.3%) 0.518
Yes 170 (14.0%) 34 (15.3%) 136 (13.7%)
PALN metastasis
a
No 1204 (98.9%) 219 (98.6%) 985 (98.9%) 0.755
Yes 14 (1.1%) 3 (1.4%) 11 (1.1%)
Adjuvant treatment
None 907 (74.5%) 159 (71.6%) 748 (75.1%) 0.242
Chemotherapy 86 (7.1%) 20 (9.0%) 66 (6.6%)
Radiation therapy 113 (9.3%) 26 (11.7%) 87 (8.7%)
CCRT 112 (9.2%) 17 (7.7%) 95 (9.5%)
Abbreviations: AdCa¼adenocarcinoma; CCRT¼concurrent chemoradiation
therapy; FIGO¼International Federation of Obstetrics and Gynecology;
LVSI¼lymphovascular space invasion; PALN¼para-aortic lymph node; SCCa¼
squamous cell carcinoma.
aA total of 731 patients underwent para-aortic
lymphadenectomy.
Table 2 The anatomic location of tumour at first recurrence by
histologic type of tumour (N¼122)
Location of
Histologic type
tumour SCCa AdCa Total
Pelvis 38 (42.2%) 8 (25.0%) 46 (37.7%)
Outside pelvis 62 (67.8%) 24 (75.0%) 76 (62.3%)
Abdomen
a 1 (1.1%) 7 (21.9%) 8 (6.6%)
Distant metastasis
b 42 (46.7%) 11 (34.4%) 53 (43.4%)
Pelvis and
abdomen
3 (3.3%) 4 (12.5%) 7 (5.7%)
Pelvis and distant
metastasis
3 (3.3%) 2 (6.3%) 5 (4.1%)
Abdomen and
distant metastasis
2 (2.2%) 0 (0%) 2 (1.6%)
Pelvis, abdomen and
distant metastasis
1 (1.1%) 0 (0%) 1 (0.8%)
Total 90 (100.0%) 32 (100.0%) 122 (100.0%)
Abbreviations: AdCa¼adenocarcinoma; SCCa¼squamous cell carcinoma.
aAbdominal peritoneal metastasis.
bHaematogenous metastasis to extraperitoneal
organs.
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(inclusion criteria, Po0.05; exclusion criteria, P40.1). P-values
o0.05 in two-sided tests were regarded as significant. Data
analyses were performed using SPSS for Windows (version 11.0;
SPSS Inc., Chicago, IL, USA). Power calculations were performed
using NCSS software (version 2004; NCSS Inc., Kaysville, UT,
USA). A two-sided log-rank test with an overall sample size of 1218
subjects (222 in group 1 and 996 in group 2) was calculated to
achieve 92% power at a 0.05 significance level to detect a difference
of 0.08 between 0.82 and 0.90, the proportions surviving in groups
Table 3 Univariate analyses of clinicopathologic parameters on
recurrence-free and overall survival in patients with adenocarcinoma
Adenocarcinoma
(n¼222)
Recurrence-free
survival
Overall
survival
Variables N (%)
5-year
rate (%) P-value
5-year
rate (%) P-value
Age, years
As continuous
variable
222 (100) 0.153 0.073
o30 5 (2.3) 80 0.250 80 0.096
30–49 141 (63.5) 89 93
450 76 (34.2) 81 86
FIGO stage
IA2 8 (3.6%) 100 o0.001 100 o0.001
IB1–IB2 195 (87.8%) 89 92
IIA 19 (8.6%) 52 65
Histologic subtype
Mucinous 203 (16.7%) 87 0.373 90 0.425
Endometrioid 14 (1.1%) 77 84
Serou 2 (0.2%) 50 50
Mixed 3 (0.2%) 100 100
Grade of differentiation
a
Well 63 (29.0) 88 0.688 90 0.532
Moderately 94 (43.3) 83 91
Poorly 60 (27.6) 87 89
Tumour size, cm
p2 108 (48.6) 91 0.041 95 0.033
2–4 94 (42.3) 82 85
4–6 20 (9.0) 77 90
46 0 (0.0) — —
Depth of stromal invasion
p1/2 135 (60.8) 92 0.002 94 0.008
41/2 87 (39.2) 78 84
Parametrial involvement
No 200 (90.1) 89 o0.001 92 o0.001
Yes 22 (9.9) 55 66
Resection margin
Negative 218 (98.2) 87 0.013 91 0.005
Positive 4 (1.8) 38 38
LVSI
No 189 (85.1) 88 0.033 92 0.026
Yes 33 (14.9) 75 80
Lymph node metastasis
No 188 (84.7) 90 o0.001 94 o0.001
Yes 34 (15.3) 66 69
Adjuvant treatment
None 159 (71.6) 89 0.003 94 o0.001
Chemotherapy 20 (9.0) 88 95
Radiation therapy 26 (11.7) 76 77
CCRT 11 (7.7) 71 70
Abbreviations: CCRT¼concurrent chemoradiation therapy; FIGO¼International
Federation of Obstetrics and Gynecology; LVSI¼lymphovascular space invasion.
aGrade of differentiation was undetermined in 21 patients.
Table 4 Univariate analyses of clinicopathologic parameters on
recurrence-free and overall survival in patients with squamous cell
carcinoma
Squamous cell carcinoma (n¼996)
Recurrence-free
survival
Overall
survival
Variables N
5-year
rate (%) P-value
5-year
rate (%) P-value
Age, years
As continuous
variable
996 (100) o0.001 o0.001
o30 16 (1.6) 94 o0.001 94 o0.001
30–49 574 (57.6) 94 97
450 406 (40.8) 88 91
FIGO stage
IA2 80 (8.0) 100 0.002 100 0.061
IB1–IB2 824 (82.7) 92 94
IIA 92 (9.3) 83 91
Grade of differentiation
a
Well 269 (27.4) 92 0.705 93 0.896
Moderately 479 (48.8) 92 94
Poorly 234 (23.8) 90 93
Tumour size, cm
p2 463 (46.5) 97 o0.001 98 o0.001
2–4 416 (41.8) 89 92
4–6 94 (9.4) 80 87
46 23 (2.3) 75 77
Depth of stromal invasion
p1/2 618 (62.0) 94 o0.001 95 0.001
41/2 378 (38.0) 87 91
Parametrial involvement
No 906 (91.0) 93 o0.001 95 o0.001
Yes 90 (9.0) 78 82
Resection margin
Negative 972 (97.6) 92 0.399 94 0.170
Positive 24 (2.4) 96 100
LVSI
No 780 (78.3) 93 o0.001 95 0.003
Yes 216 (21.7) 87 90
Lymph node metastasis
No 860 (86.3) 93 o0.001 95 o0.001
Yes 136 (13.7) 82 85
Adjuvant treatment
None 748 (75.1) 94 o0.001 96 o0.001
Chemotherapy 66 (6.6) 89 91
Radiation therapy 87 (8.7) 84 87
CCRT 95 (9.5) 82 85
Abbreviations: CCRT¼concurrent chemoradiation therapy; FIGO¼International
Federation of Obstetrics and Gynecology; LVSI, lymphovascular space invasion.
aGrade of differentiation was undetermined in 21 patients.
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s1 and 2, respectively. This corresponded to a hazard ratio of 0.53.
The proportion of patients lost during follow-up was 0.05. These
results were based on the assumption that the hazard rates were
proportional.
RESULTS
During the study period, 1218 patients met all inclusion criteria. Of
these, 996 patients (81.8%) had SCCa and 222 (18.2%) had AdCa.
Of the 222 patients with AdCa, 203 had mucinous-type tumours,
14 had endometrioid-type tumours, 2 had serous-type tumours
and 3 had mixed-type tumours. The characteristics of these
patients are shown in Table 1. Patients with AdCa were signi-
ficantly younger than those with SCCa. Lymphovascular space
invasion was more frequent is patients with AdCa compared with
those with SCCa. However, FIGO stage, grade of differentiation,
tumour size, depth of cervical stromal invasion, parametrial
involvement, resection margin status and lymph node metastasis
did not differ between the two histologic groups.
Patients with FIGO stage IA2 disease (n¼88) underwent type II
hysterectomy with pelvic and/or para-aortic lymphadenectomy
and patients with FIGO stage IB1–IIA disease (n¼1130) under-
went type III hysterectomy with pelvic and/or para-aortic
lymphadenectomy. Thus, all patients underwent pelvic lympha-
denectomy, and 731 underwent para-aortic lymphadenectomy. Of
the 1218 patients, 311 (25.6%) received postoperative adjuvant
therapy. There were no differences in the proportion of patients
who received postoperative adjuvant therapy and in the type of
adjuvant therapy between the two histologic groups (Table 1).
Survival and patterns of recurrence in patients with
AdCa and SCCa
The overall median and mean follow-up times were 91 and
83 months (range, 10–236 months) for all patients, respectively,
73 and 81 months (range, 11–231 months), respectively, in
patients with AdCa and 85 and 92 months (range, 10–236
months), respectively, in patients with SCCa (AdCa vs SCCa,
P¼0.012). Of the 1218 patients, 419 had follow-up durations of
o60 months, with 137 lost to follow-up for over 1 year at the time
of this analysis. Of these, 29 had AdCa and 108 had SCCa, making
the rates of loss during follow-up 13.1% (29 out of 222) for the
AdCa group, and 10.8% (108 out of 996) for the SCCa group
(P¼0.344). The mean and median follow-up times of patients lost
to follow-up were 41 and 43 months (range, 14–59 months),
respectively, for the AdCa group, and 43 and 41 months (range,
10–59 months), respectively, for the SCCa group (P¼0.440). The
5-year and 10-year RFS rates in patients with AdCa were 86 and
82%, respectively, and the 5-year and 10-year RFS rates in patients
with SCCa were 92 and 90%, respectively (P¼0.009). The 5-year
and 10-year OS rates in patients with AdCa were 90 and 83%,
respectively, and the 5-year and 10-year OS rates in patients with
SCCa were 94 and 91%, respectively (Po0.001). At the time of this
analysis, 32 patients (14.4%) in AdCa group and 90 patients (9.0%)
in SCCa group had cancer recurrence (P¼0.016), and 30 patients
(13.5%) in AdCa group and 71 patients (7.1%) in SCCa died
of disease (P¼0.002). The mean times to recurrence in the AdCa
and SCCa groups were 36 months (range, 6–152 months) and
34 months (range, 2–156 months), respectively (P¼0.805).
The anatomic location of tumour at first recurrence was outside
the pelvis in 57.8 and 75.0% of patients with SCCa and AdCa,
respectively (P¼0.084) (Table 2). Recurrent tumours in these
patients were observed in the abdomen, skin, muscle, bone, liver,
lung, meninx, brain and/or lymph nodes.
The treatment modality or strategy was not altered over
time. Therefore, we divided the study period arbitrarily into
three 6-year intervals (1989–1994, n¼156; 1995–2000, n¼371;
and 2001–2006, n¼691). However, we found that 5-year disease-
free survival rates (95, 92 and 90%, respectively, P¼0.1425) and
5-year OS rates (97, 94 and 92%, respectively, P¼0.1889) did not
differ by time.
Prognostic factors associated with RFS and OS in patients
with AdCa and SCCa
In 222 patients with AdCa, FIGO stage, tumour size, depth of
cervical stromal invasion, parametrial involvement, resection
margin status, LVSI, lymph node metastasis and type of adjuvant
treatment were significantly associated with both RFS and OS in
univariate analysis, whereas age, grade of differentiation and
histologic subtype were unrelated (Table 3). After adjusting for
factors significant in univariate analysis, multivariate analysis
showed that parametrial involvement and lymph node metastasis
were significant factors for both RFS and OS (Table 4).
In 996 patients with SCCa, age, tumour size, depth of cervical
stromal invasion, parametrial involvement, LVSI, lymph node
metastasis and type of adjuvant treatment were significantly
associated with both RFS and OS, but FIGO stage was significantly
associated with only RFS in univariate analysis, whereas resection
margin status and grade of differentiation were unrelated (Table 5).
After adjusting for factors significant in univariate analysis,
multivariate analysis showed that age, tumour size, parametrial
involvement and lymph node metastasis were significant factors
for both RFS and OS (Table 6).
When analysing 1218 patients with AdCa and SCCa, age,
FIGO stage, histologic type, tumour size, depth of cervical
stromal invasion, parametrial involvement, LVSI, lymph node
metastasis and type of adjuvant treatment were significantly
associated with both RFS and OS, whereas resection margin
status and grade of differentiation were unrelated (Table 7). After
adjusting for factors significant in univariate analysis, multivariate
analysis showed that age, histologhic type, tumour size, para-
metrial involvement and lymph node metastasis were significant
factors for both RFS and OS (Table 8). Relative to patients
with SCCa, the probability of cancer recurrence was significantly
higher in patients with AdCa (odds ratio (OR)¼2.07, 95%
confidence interval (CI)¼1.37–3.12, P¼0.001) after adjusting
factors significant in univariate analysis. Moreover, the probability
of cancer death was significantly higher in patients with AdCa
(OR¼2.56, 95% CI¼1.65–3.96, Po0.001) compared with
patients with SCCa after adjusting factors significant in univariate
analysis.
Table 5 Multivariate analyses of clinicopathologic parameters on
recurrence-free and overall survival in patients with adenocarcinoma
Adenocarcinoma (n¼222)
Recurrence-free survival
a Overall survival
a
Variables N OR (95% CI) P-value OR (95% CI) P-value
Parametrial involvement
No 200 (90.1) Reference Reference
Yes 22 (9.9) 3.46 (1.46–8.19) 0.005 6.17 (2.55–14.95) 0.002
Lymph node metastasis
No 188 (84.7) Reference Reference
Yes 34 (15.3) 2.45 (1.14–5.30) 0.022 2.79 (1.25–6.25) 0.012
Abbreviations: CI¼confidence interval; LVSI¼lymphovascular space invasion;
OR¼odds ratio.
aThe analysis included FIGO stage, tumour size, depth of stromal
invasion, parametrial involvement, resection margin, LVSI, lymph node metastasis, and
adjuvant treatment.
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In our series, the survival outcomes after RH followed by tailored
adjuvant therapy according to postoperative risk factors in patients
with IA2–IIA AdCa of uterine cervix were excellent because 5-year
RFS and OS were 86 and 90%, respectively. Parametrial involvement
and lymph node metastasis were independent prognostic factors in
patients with AdCa as were they in patients with SCCa. Therefore,
this treatment strategy for IA2–IIA AdCa of uterine cervix seems
acceptable as with SCCa. However, in spite of the distribution of
postoperative risk factors, the proportion of patients who received
adjuvant therapy, and type of adjuvant therapy were not different
between AdCa and SCCa groups, the RFS and OS were significantly
poorer in AdCa group compared with SCCa group in multivariate
analysis although the survival differences were not much. The time
interval to recurrence was not different between AdCa and SCCa
groups, but recurrence outside pelvis was more frequent in AdCa
groups. This may suggest that AdCa has somewhat aggressive
behaviour with propensity of distant metastasis and systemic
adjuvant therapy might be beneficial for AdCa.
It has long been unclear whether prognosis of patients with
early-stage cervical cancer undergoing RH was dependent on
histologic type. Although some studies included a significant
number of subjects, most previous reports had small cohorts of
patients, with numbers insufficient to determine small differences
in RFS and OS. Hence, because the survival of surgically treated
patients with early-stage cervical cancer is excellent, the magnitude
of differences in RFS and OS among different histologic types is
small. Previous studies have reported that the magnitude of
differences in 5-year RFS and OS rates ranged from 2.0 to 9.0%,
findings similar to ours (Look et al, 1996; Lai et al, 1999; Nakanishi
et al, 2000; Ayhan et al, 2004; Fregnani et al, 2008). As far as we
know, our series is one of the largest studies which compared the
survival outcomes of early-stage AdCa and SCCa. The survival
difference between AdCa and SCCa groups was small but
significant. In our series, a two-sided log-rank test with an overall
sample size of 1218 subjects (of which 222 are in AdCa group and
996 are in SCCa group) achieved 80% power at a 0.05 significance
level to detect a difference of 6% in 10-year DFS between 86 and
92%, the proportions surviving in AdCa group and SCCa group,
Table 6 Multivariate analyses of clinicopathologic parameters on
recurrence-free and overall survival in patients with squamous cell
carcinoma
Squamous cell
carcinoma (n¼996)
Recurrence-free
survival
a
Overall
survival
b
Variables N
OR
(95% CI) P-value
OR
(95% CI) P-value
Age, years
As
continuous
variable
996 (100) 1.05 (1.03–1.07) o0.001 1.05 (1.03–1.07) o0.001
Tumour size, cm
p2 463 (46.5) Reference Reference
2–4 416 (41.8) 2.25 (1.30–3.89) 0.004 2.12 (1.16–3.88) 0.015
4–6 94 (9.4) 4.51 (2.32–8.78) o0.001 3.51 (1.64–7.50) 0.001
46 23 (2.3) 6.36 (2.43–16.68) o0.001 5.11 (1.73–15.14) 0.003
Parametrial involvement
No 906 (91.0) Reference Reference
Yes 90 (9.0) 1.78 (1.01–3.12) 0.046 2.17 (1.13–4.13) 0.019
Lymph node metastasis
No 860 (86.3) Reference Reference
Yes 136 (13.7) 1.86 (1.12–3.09) 0.017 2.11 (1.18–3.75) 0.012
Abbreviations: CI¼confidence interval; LVSI¼lymphovascular space invasion;
OR¼odds ratio.
aThe analysis included age, FIGO stage, tumour size, depth of
stromal invasion, parametrial involvement, LVSI, lymph node metastasis and adjuvant
treatment.
bThe analysis included age, tumour size, depth of stromal invasion,
parametrial involvement, LVSI, lymph node metastasis and adjuvant treatment.
Table 7 Univariate analyses of clinicopathologic parameters on
recurrence-free and overall survival in all patients (n¼1218)
Recurrence-free
survival
Overall
survival
Variables
No. of
patients
5-year
rate (%) P-value
5-year
rate (%) P-value
Age, years
As continuous
variable
1218 (100%) o0.001 o0.001
o30 21 (1.7%) 90 o0.001 90 o0.001
30–49 715 (58.7%) 93 96
450 482 (39.6%) 87 90
FIGO stage
IA2 88 (7.2%) 100 o0.001 100 o0.001
IB1–IB2 1019 (83.7%) 91 93
IIA 111 (9.1%) 80 86
Histology
SCCa 996 (81.8%) 92 0.008 94 o0.001
AdCa 222 (18.2%) 86 90
Grade of differentiation
a
Well 332 (27.3%) 91 0.902 93 0.967
Moderately 573 (47.0%) 91 94
Poorly 294 (24.1%) 89 92
Tumour size, cm
p2 571 (46.9%) 96 o0.001 97 o0.001
2–4 510 (41.9%) 88 91
4–6 114 (9.4%) 80 87
4 6 23 (1.9%) 75 77
Depth of stromal invasion
p1 out of 2 753 (61.8%) 94 o0.001 95 o0.001
41 out of 2 465 (38.2%) 85 90
Parametrial involvement
No 1106 (90.8%) 92 o0.001 95 o0.001
Yes 112 (9.2%) 74 79
Resection margin
Negative 1190 (97.7%) 91 0.911 93 0.803
Positive 28 (2.2%) 89 93
LVSI
No 1048 (86.0%) 92 o0.001 94 o0.001
Yes 170 (14.0%) 85 89
Lymph node metastasis
No 1111 (85.5%) 93 o0.001 95 o0.001
Yes 188 (14.5%) 78 82
Adjuvant treatment
None 907 (74.5%) 93 o0.001 95 o0.001
Chemotherapy 86 (7.1%) 89 92
Radiation therapy 113 (9.3%) 82 85
CCRT 112 (9.2%) 80 83
Abbreviations: AdCa¼adenocarcinoma; CCRT¼concurrent chemoradiation
therapy; FIGO¼International Federation of Obstetrics and Gynecology;
LVSI¼lymphovascular space invasion; SCCa¼squamous cell carcinoma.
aGrade of
differentiation was undetermined in 21 patients.
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1218 subjects (of which 222 are in AdCa group and 996 are in SCCa
group) achieved 92% power at a 0.05 significance level to detect a
difference of 8% in 10-year OS between 82 and 90%, the proportions
surviving in AdCa group and SCCa group, respectively.
Although we found that patients with AdCa had significantly
poorer prognosis than those with SCCa, after adjusting for other
significant prognostic factors, the magnitude of differences in RFS
and OS were small and the RFS and OS of patients with AdCa and
AdSCCa were still good. Therefore, the current management
strategy for patients with early-stage AdCa, consisting of RH
followed tailored adjuvant therapy according to postoperative risk
factors, should be acceptable.
Of the 20 patients with AdCas 4–6cm in diameter, 4 had
recurrent disease and 3 of these died of disease within 5 years,
making the 5-year DFS and OS rates 77 and 90%, respectively.
The fourth patient with recurrence died of disease at 78 months,
making the survival rate at 78 months 80%, similar to the 40–70%
OS rates previously reported.
It is still not clear whether histologic type has an effect on time
to recurrence after RH, or on the patterns of spread and
recurrence. Although several studies reported that the time to
recurrence was shorter in patients with AdCa and AdSCCa than in
those with SCCa, more recent work has found no difference
associated with histologic type (Look et al, 1996; Lai et al, 1999).
When classified into recurrence inside and outside the pelvis, the
pattern of spread and recurrence did not differ among histologic
groups in some studies (Look et al, 1996; Lai et al, 1999; Grisaru
et al, 2001), whereas other reports showed an association between
histologic type and more frequent disseminated peritoneal
spread or distant metastasis (Drescher et al, 1989; Eifel et al,
1995; Kasamatsu et al, 2009). In our series, recurrence outside the
pelvis was more frequent in patients with AdCa. As a result of the
absence of curative systemic therapy, patients with recurrence
outside the pelvis tend to perform very poorly; however, patients
with isolated pelvic recurrence are frequently salvaged with pelvic
RT with or without concurrent chemotherapy. This may be one
reason for the differences in OS observed among histologic types.
Therefore, to improve the survival of patients with AdCa after RH,
more effective systemic adjuvant therapies are required.
Consistently reported independent adverse prognostic factors
for patients with early-stage cervical cancer after RH include
higher FIGO stage, lymph node metastasis, parametrial involve-
ment, depth of cervical stromal invasion, tumour size and LVSI
(Look et al, 1996; Lai et al, 2007; Kasamatsu et al, 2009). We also
found that these factors were significant in univariate analysis,
although only lymph node metastasis, parametrial involvement
and tumour size were significant in multivariate analysis. Some
investigators reported that AdCa was more frequently associated
with these prognostic factors than SCCa (Kasamatsu et al, 2009).
However, other studies found no significant association between
these factors and histologic type (Shingleton et al, 1995; Look et al,
1996; Nakanishi et al, 2000; Fregnani et al, 2008). In our series,
there were no differences in FIGO stage, tumour size, depth of
cervical stromal invasion, parametrial involvement, LVSI or lymph
node metastasis between patients with the two histologic types.
In conclusion, we found that the clinicopathologic charac-
teristics and time interval to recurrence did not differ between
histologic types. However, recurrence outside the pelvis was more
frequent in patients with AdCa than in those with SCCa. Moreover,
patients with AdCa had significantly poorer RFS and OS than did
those with SCCa. Nevertheless, the current treatment strategy of
RH on patients with AdCa is acceptable because the RFS and OS
were still excellent. However, more effective systemic adjuvant
therapies after RH are needed for patients with AdCa.
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